Overall, the quantitative MSP results validated what was shown in the MBD and sequencing data; the targeted ANK2 intron 21 and EPAS1 intron 1 regions are hypermethylated in CMT and are candidate tissue biomarkers for this disease. This evidence concerns the gene EPAS1 and Charcot-Marie-Tooth disease.